CCR5 and gastric cancer: Since several studies have demonstrated its involvement in GC progression [48,101,106,110], counteracting the pro-tumorigenic effects of the CCL5/CCR5 axis with CCR5-antagonists, such as MVC [53,111], or alternatively, with drugs that are capable to of decreasing CCL5 secretion [69] may be a new therapeutic options for GC treatment.